

Methods in
Molecular Biology 1715

Springer Protocols



Camiel J.F. Boon
Jan Wijnholds *Editors*

Retinal Gene Therapy

Methods and Protocols

 Humana Press

METHODS IN MOLECULAR BIOLOGY

Series Editor
John M. Walker
School of Life and Medical Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Retinal Gene Therapy

Methods and Protocols

Edited by

Camiel J.F. Boon

*Department of Ophthalmology, Leiden University Medical Center (LUMC),
Leiden, The Netherlands; Department of Ophthalmology, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands*

Jan Wijnholds

*Department of Ophthalmology, Leiden University Medical Center (LUMC),
Leiden, The Netherlands; Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and
Sciences (KNAW), Amsterdam, The Netherlands*

Editors

Camiel J.F. Boon
Department of Ophthalmology
Leiden University Medical Center (LUMC)
Leiden, The Netherlands

Department of Ophthalmology
Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands

Jan Wijnholds
Department of Ophthalmology
Leiden University Medical Center (LUMC)
Leiden, The Netherlands

Netherlands Institute for Neuroscience
Royal Netherlands Academy of Arts
and Sciences (KNAW)
Amsterdam, The Netherlands

ISSN 1064-3745 ISSN 1940-6029 (electronic)
Methods in Molecular Biology
ISBN 978-1-4939-7521-1 ISBN 978-1-4939-7522-8 (eBook)
<https://doi.org/10.1007/978-1-4939-7522-8>

Library of Congress Control Number: 2017959612

© Springer Science+Business Media LLC 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by Springer Nature
The registered company is Springer Science+Business Media, LLC
The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

Preface

The eye is in the frontline of gene therapy development. As a relatively closed compartment, it is on the one hand relatively isolated and immune-privileged from the rest of the body, yet at the same time well-accessible to surgical intervention and a broad range of clinical examinations of its structure and function. The eye is therefore an attractive target organ for the application of gene therapy. With more than 2000 clinical trials to date for a wide range of genetic diseases, ocular gene therapy offers a promising perspective for the more than currently known 250 retinal disease genes. A preferred delivery system are the adeno-associated viral (AAV) gene therapy vectors for gene augmentation, gene editing, and miRNA delivery, next to the antisense oligonucleotide delivery system. As in preclinical studies, ocular clinical gene therapy studies know their successes and disappointments. The first successful ocular clinical studies for the orphan drug AAV-*RPE65* for Leber congenital amaurosis and retinitis pigmentosa were reported in the literature in 2008. More than a decade later, AAV-*RPE65* retinal gene therapy approaches are evaluated in phase 3 clinical studies and reached market approval. Clinical development of retinal gene therapy is yet a time-consuming process for technological as well financial reasons, but many more successes are expected in the coming decade for ocular gene augmentation, gene editing, miRNA delivery, as well as the antisense oligonucleotide delivery system.

This volume of *Methods in Molecular Biology* describes a spectrum of methods and protocols that can be used for the bench-to-bedside development and evaluation of retinal gene therapy. Methods for the successful delivery of these gene therapy vector systems to the retina are reviewed, as well as assays to test the efficacy in vitro in cell cultures; in vivo on rodents, pigs, and monkey retinas; and on human retinal explants as well as in human clinical studies. Chapters in this book are organized into three major parts: Part I elaborates on the production of retinal gene therapy vectors and testing these in biological assays in vitro. Part II describes assays for gene augmentation and gene editing in vivo on rodent, pig, and macaque retina. Part III highlights clinical protocols and retinal gene therapy vector testing on human retina. Written in the highly successful *Methods in Molecular Biology* series format, chapters include introductions to their respective topics, with step-by-step lists of the necessary materials and reagents, readily reproducible laboratory protocols, and tips on troubleshooting and how to avoid known pitfalls.

The preparation of AAVs is a relatively simple task for the ones skilled in molecular biology, but robust protocols are needed to obtain high-quality high-titer stocks of AAV. In Part I, we have included three of such chapters, Chapters 1–3, describing detailed various techniques to produce microscale and small-scale batches of AAVs with useful notes on the various steps in the production. AAVs have a limited packaging capacity compared to lentiviral vectors, but vectors with multiple gene cassettes enabling cell-specific co-expression of microRNA (miRNA) and protein factors are of high interest. In Chapter 4, we have included such an example that may contribute to the development of combination therapies for various ocular diseases. Other promising retinal gene therapy methods such as the use of antisense oligonucleotides (AONs) to correct pre-mRNA splicing defects involved in inherited retinal dystrophies are described in Chapter 5. Bioavailability and bioactivity of retinal gene delivery system products can be tested in three-dimensional co-culture assays, and these methods and protocols are described in Chapter 6. To test new gene therapy AAV gene

augmentation vectors, there is a need for reliable and sensitive *in vitro* assays to determine the expression of delivered proteins, which is covered in Chapter 7. In Part II, we highlight assays for gene augmentation and editing *in vivo* on rodent, pig, and macaque retina. Chapter 8 describes techniques to study the expression of gene therapy vectors upon *in vivo* electroporation of the developing mouse retina. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein or CRISPR/Cas gene editing of the adult retina is a powerful technique for correcting inherited ocular disease, and Chapters 9 and 13 describe methods to apply these techniques in preclinical models. Chapters 10 and 11 present protocols to detect the expression of therapeutic protein by fluorescence immunohistochemistry, histological studies using ultrathin sections, and immuno-electron microscopy and confocal laser scanning microscopy. Application techniques to deliver AAV vectors either subretinally or intravitreally into the murine retinas are described in Chapters 9–13 and 15. Very large genes cannot be expressed in a single AAV vector, but some can be expressed using dual-vector technology approaches as described in Chapter 11. Chapter 12 highlights methods for optogenetic retinal gene therapy to express light-sensitive G protein-coupled receptors (GPCRs) in retinal neurons, recording light responses in retinal explants *in vitro* by multi-electrode array (MEA), recording cortical light responses *in vivo* by visually evoked response (VEP), and testing visually guided behavior in open field test and water maze task in treated mice. Noninvasive diagnostic methods to assess retinal function and morphology *in vivo* in rodents by electroretinography (ERG) and optical coherence tomography (OCT) are discussed in Chapters 9, 13, and 14. Neutralizing antibodies (NABs) to AAVs may limit the infection capacity when administered intravitreal to the retina, and therefore, Chapters 16 and 17 are included to describe methods to screen rodent and nonhuman primate (NHP) serum for pre-existing NABs, providing useful tips and tricks. Chapters 11 and 18 focus on techniques for subretinal and intravitreal retinal injections in large animal models such as pigs and monkeys. Part III deals with clinical protocols and retinal gene therapy vector testing on human retinal explants and *in vivo* evaluation of the human retina in the context of retinal gene therapy. Natural as well as recombinant AAVs need to be tested on human tissue for their infection and expression efficacy. Chapter 19 describes iPS-derived human retina production protocols as well as methods to infect retinal cell types with AAVs. Chapters 20 and 21 highlight *ex vivo* validation on cultured retinal explants obtained from donor retina or from retinal surgery, respectively. Chapters 22–26 describe clinical protocols that can be used in retinal gene therapy studies such as visual acuity testing, electroretinography, visual field testing by Goldmann perimetry, central visual field sensitivity testing by fundus-driven perimetry also known as microperimetry, and spectral domain optical coherence tomography (SD-OCT) and OCT angiography. Methods to test vector shedding have become increasingly important with the number of AAV gene therapy trials that have started, and Chapter 27 describes standard operating protocols for these.

Retinal gene therapy is a broad field of research using various methods and protocols. This book therefore provides a wide range of readers from students to research experts with useful information on ocular gene therapy vector technology, *in vitro* and *in vivo* biological assays, and clinical protocols. We hope that the book finds its way in the scientific community to promote further studies for the benefit of children and adults with inherited retinal disease.

We thank all of the contributors for their enthusiastic and valuable contributions, the series editor John Walker, and Springer Nature for their support that made this volume possible.

Leiden, The Netherlands

*Camiel J.F. Boon
Jan Wijnholds*

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>xi</i>
PART I RETINAL GENE THERAPY VECTOR PRODUCTION AND BIOLOGICAL ASSAYS IN VITRO	
1 Small Scale Production of Recombinant Adeno-Associated Viral Vectors for Gene Delivery to the Nervous System.	3
<i>Joost Verhaagen, Barbara Hobo, Erich M.E. Ehlert, Ruben Eggers, Joanna A. Korecka, Stefan A. Hoyng, Callan L. Attwell, Alan R. Harvey, and Matthew R.J. Mason</i>	
2 Small and Micro-Scale Recombinant Adeno-Associated Virus Production and Purification for Ocular Gene Therapy Applications	19
<i>Christopher A. Reid and Daniel M. Lipinski</i>	
3 Design and Development of AAV-based Gene Supplementation Therapies for Achromatopsia and Retinitis Pigmentosa	33
<i>Christian Schön, Elvir Becirovic, Martin Biel, and Stylianos Michalakis</i>	
4 Development of Multigenic Lentiviral Vectors for Cell-Specific Expression of Antiangiogenic miRNAs and Protein Factors	47
<i>Anne Louise Askou and Thomas J. Corydon</i>	
5 Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies	61
<i>Alejandro Garanto and Rob W.J. Collin</i>	
6 Three-Dimensional Co-Culture Bioassay for Screening of Retinal Gene Delivery Systems	79
<i>Ding Wen Chen, Kathleen Pauloff, and Marianna Foldvari</i>	
7 Retinal Gene Therapy for Choroideremia: In Vitro Testing for Gene Augmentation Using an Adeno-Associated Viral (AAV) Vector	89
<i>Maria I. Patrício and Robert E. MacLaren</i>	
PART II ASSAYS FOR GENE AUGMENTATION AND EDITING IN VIVO ON RODENT AND MACAQUE RETINA	
8 In Vivo Electroporation of Developing Mouse Retina	101
<i>Jimmy de Melo and Seth Blackshaw</i>	
9 Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina	113
<i>Sandy S. Hung, Fan Li, Jiang-Hui Wang, Anna E. King, Bang V. Bui, Guei-Sheung Liu, and Alex W. Hewitt</i>	
10 AAV Gene Augmentation Therapy for <i>CRB1</i> -Associated Retinitis Pigmentosa	135
<i>C. Henrique Alves and Jan Wijnholds</i>	

11	Dual AAV Vectors for Stargardt Disease	153
	<i>Ivana Trapani</i>	
12	Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin	177
	<i>Benjamin M. Gaub, Michael H. Berry, Meike Visel, Amy Holt, Ehud Y. Isacoff, and John G. Flannery</i>	
13	CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology	191
	<i>Wen-Hsuan Wu, Yi-Ting Tsai, Sally Justus, Galaxy Y. Cho, Jesse D. Sengillo, Yu Xu, Thiago Cabral, Chyuan-Sheng Lin, Alexander G. Bassuk, Vinit B. Mahajan, and Stephen H. Tsang</i>	
14	In-Depth Functional Analysis of Rodents by Full-Field Electroretinography	207
	<i>Vithiyanjali Sothilingam, Regine Mühlfriedel, Naoyuki Tanimoto, and Mathias W. Seeliger</i>	
15	Advanced Ocular Injection Techniques for Therapy Approaches	215
	<i>Regine Mühlfriedel, Marina Garcia Garrido, Christine Wallrapp, and Mathias W. Seeliger</i>	
16	Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery	225
	<i>Mélissa Desrosiers and Deniz Dalkara</i>	
17	Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas	239
	<i>Timothy P. Day, Leah C. Byrne, John G. Flannery, and David V. Schaffer</i>	
18	Subretinal and Intravitreal Retinal Injections in Monkeys	251
	<i>Daniyar Dauletbekov, K. Ulrich Bartz-Schmidt, and M. Dominik Fischer</i>	
PART III CLINICAL PROTOCOLS AND RETINAL GENE THERAPY VECTOR TESTING ON HUMAN RETINA		
19	Production of iPS-Derived Human Retinal Organoids for Use in Transgene Expression Assays	261
	<i>Peter M. Quinn, Thilo M. Buck, Charlotte Ohonin, Harald M.M. Mikkers, and Jan Wijnholds</i>	
20	AAV Serotype Testing on Cultured Human Donor Retinal Explants	275
	<i>Thilo M. Buck, Lucie P. Pellissier, Rogier M. Vos, Elon H.C. van Dijk, Camiel J.F. Boon, and Jan Wijnholds</i>	
21	Human Retinal Explant Culture for Ex Vivo Validation of AAV Gene Therapy	289
	<i>Harry O. Orlans, Thomas L. Edwards, Samantha R. De Silva, Maria I. Patrício, and Robert E. MacLaren</i>	
22	Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients	305
	<i>Bin Li and Chenmian Wu</i>	
23	Recording and Analysis of the Human Clinical Electroretinogram	313
	<i>Mathieu Gauvin, Allison L. Dorfman, and Pierre Lachapelle</i>	

24 Recording and Analysis of Goldmann Kinetic Visual Fields 327
Mays Talib, Gislín Dagnelie, and Camiel J.F. Boon

25 Measuring Central Retinal Sensitivity Using Microperimetry 339
Mays Talib, Jasleen K. Jolly, and Camiel J.F. Boon

26 Inspection of the Human Retina by Optical Coherence Tomography 351
Thomas Theelen and Michel M. Teussink

27 Vector Shedding and Immunogenicity Sampling for Retinal Gene Therapy . . . 359
Alun R. Barnard, Anna N. Rudenko, and Robert E. MacLaren

Index 373

Contributors

- C. HENRIQUE ALVES • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*
- ANNE LOUISE ASKOU • *Department of Biomedicine, Aarhus University, Aarhus, Denmark*
- CALLAN L. ATTWELL • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands*
- ALUN R. BARNARD • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK*
- K. ULRICH BARTZ-SCHMIDT • *University Eye Hospital, University of Tübingen, Tübingen, Germany*
- ALEXANDER G. BASSUK • *Department of Pediatrics and Neurology, University of Iowa, Iowa City, IA, USA*
- ELVIR BECIROVIC • *Department of Pharmacy, Center for Drug Research, Center for Integrated Protein Science Munich CiPSM, Ludwig-Maximilian-University, Munich, Germany*
- MICHAEL H. BERRY • *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA*
- MARTIN BIEL • *Department of Pharmacy, Center for Drug Research, Center for Integrated Protein Science Munich CiPSM, Ludwig-Maximilian-University, Munich, Germany*
- SETH BLACKSHAW • *Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Human Systems Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA*
- CAMIEL J.F. BOON • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands*
- THILO M. BUCK • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*
- BANG V. BUI • *Department of Optometry & Vision Sciences, University of Melbourne, Parkville, VIC, Australia*
- LEAH C. BYRNE • *The Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA; Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA*
- THIAGO CABRAL • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA; Department of Ophthalmology, Federal University of Sao Paulo (UNIFESP), São Paulo, Brazil; Department of Ophthalmology, Federal University of Espírito Santo (UFES), Vitória, Brazil*

- DING WEN CHEN • *School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, Waterloo, ON, Canada*
- GALAXY Y. CHO • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA*
- ROB W.J. COLLIN • *Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands*
- THOMAS J. CORYDON • *Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark*
- GISLIN DAGNELIE • *Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA*
- DENIZ DALKARA • *INSERM, U968, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France; CNRS, UMR_7210, Paris, France*
- DANIYAR DAULETBEKOV • *University Eye Hospital, University of Tübingen, Tübingen, Germany; Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany; Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, UK*
- TIMOTHY P. DAY • *The Helen Wills Neuroscience Institute, The University of California at Berkeley, Berkeley, CA, USA*
- SAMANTHA R. DE SILVA • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK*
- MÉLISSA DESROSIERS • *INSERM, U968, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France; CNRS, UMR_7210, Paris, France*
- ELON H.C. VAN DIJK • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*
- ALLISON L. DORFMAN • *Department of Ophthalmology & Neurology-Neurosurgery, Research Institute of the McGill University Health Centre/Montreal Children's Hospital, Montreal, QC, Canada*
- THOMAS L. EDWARDS • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK*
- RUBEN EGGERS • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands*
- ERICH M.E. EHLERT • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands; UniQure, Amsterdam, The Netherlands*
- M. DOMINIK FISCHER • *University Eye Hospital, University of Tübingen, Tübingen, Germany; Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany; Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, UK*
- JOHN G. FLANNERY • *The Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA; Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA; Vision Science, University of California Berkeley, Berkeley, CA, USA*
- MARIANNA FOLDVARI • *Vision Science Graduate Group, School of Optometry, University of California, Berkeley, CA, Canada*

- ALEJANDRO GARANTO • *Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands*
- MARINA GARCIA GARRIDO • *Division of Ocular Neurodegeneration, Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany*
- BENJAMIN M. GAUB • *Department of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule (ETH) Zürich, Basel, Switzerland*
- MATHIEU GAUVIN • *Department of Ophthalmology & Neurology-Neurosurgery, Research Institute of the McGill University Health Centre/Montreal Children's Hospital, Montreal, QC, Canada*
- ALAN R. HARVEY • *School of Anatomy, Physiology and Human Biology, The University of Western Australia, Crawley, WA, Australia; Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia*
- ALEX W. HEWITT • *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia; Menzies Institute for Medical Research, School of Medicine, University of Tasmania, Hobart, TAS, Australia; Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, VIC, Australia*
- BARBARA HOBO • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands*
- AMY HOLT • *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA*
- STEFAN A. HOYNG • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands; Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands*
- SANDY S. HUNG • *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia*
- EHUD Y. ISACOFF • *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA; Physical Bioscience Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA*
- JASLEEN K. JOLLY • *Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK; Nuffield Laboratory of Ophthalmology and Oxford Biomedical Research Center, University of Oxford, Oxford, UK*
- SALLY JUSTUS • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA*
- ANNA E. KING • *Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, TAS, Australia*
- JOANNA A. KORECKA • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands; Neuroregeneration Research Institute, McLean Hospital/Harvard Medical School, Belmont, MA, USA*
- PIERRE LACHAPPELLE • *Department of Ophthalmology & Neurology-Neurosurgery, Research Institute of the McGill University Health Centre/Montreal Children's Hospital, Montreal, QC, Canada*
- BIN LI • *Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China*

- FAN LI • *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia; Menzies Institute for Medical Research, School of Medicine, University of Tasmania, Hobart, TAS, Australia*
- CHYUAN-SHENG LIN • *Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA*
- GUEI-SHEUNG LIU • *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia; Menzies Institute for Medical Research, School of Medicine, University of Tasmania, Hobart, TAS, Australia; Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, VIC, Australia*
- DANIEL M. LIPINSKI • *Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, WI, USA; Nuffield Laboratory of Ophthalmology, Department of Clinical Neuroscience, University of Oxford, Oxford, UK*
- ROBERT E. MACLAREN • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Moorfields Eye Hospital, NHS Foundation Trust, London, UK*
- VINIT B. MAHAJAN • *Omics Laboratory, Stanford University, Palo Alto, CA, USA; Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA, USA*
- MATTHEW R.J. MASON • *Netherlands Institute for Neurosciences, Amsterdam, The Netherlands*
- JIMMY DE MELO • *Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA*
- STYLIANOS MICHALAKIS • *Department of Pharmacy, Center for Drug Research, Center for Integrated Protein Science Munich CiPSM, Ludwig-Maximilian-University, Munich, Germany*
- HARALD M.M. MIKKERS • *Department of Molecular Cell Biology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*
- REGINE MÜHLFRIEDEL • *Division of Ocular Neurodegeneration, Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany*
- CHARLOTTE OHONIN • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*
- HARRY O. ORLANS • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Moorfields Eye Hospital, London, UK*
- MARIA I. PATRÍCIO • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK*
- KATHLEEN PAULOFF • *Department of Applied Health Sciences, University of Waterloo, Waterloo, ON, Canada*
- LUCIE P. PELLISSIER • *Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands; Unité Physiologie de la Reproduction et des Comportements, INRA UMR85, Centre National de la Recherche Scientifique*

UMR-7247, Institut Français du Cheval et de l'Équitation, Université François Rabelais, Nouzilly, France

PETER M. QUINN • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*

CHRISTOPHER A. REID • *Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, WI, USA*

ANNA N. RUDENKO • *Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK*

DAVID V. SCHAFFER • *The Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA; Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA; Department of Bioengineering, University of California, Berkeley, CA, USA; Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA, USA*

CHRISTIAN SCHÖN • *Department of Pharmacy, Center for Drug Research, Center for Integrated Protein Science Munich CiPSM, Ludwig-Maximilian-University, Munich, Germany*

MATHIAS W. SEELIGER • *Division of Ocular Neurodegeneration, Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany*

JESSE D. SENGILLO • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA; State University of New York Downstate Medical Center, Brooklyn, NY, USA*

VITHIYANJALI SOTHILINGAM • *Division of Ocular Neurodegeneration, Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany*

MAYS TALIB • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands*

NAOYUKI TANIMOTO • *Department of Ophthalmology, University Hospital Schleswig-Holstein, Kiel, Germany*

MICHEL M. TEUSSINK • *Department of Ophthalmology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands*

THOMAS THEELEN • *Department of Ophthalmology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands*

IVANA TRAPANI • *Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy*

YI-TING TSAI • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA*

STEPHEN H. TSANG • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA; Department of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Edward S. Harkness Eye Institute, Columbia University, New York, NY, USA*

JOOST VERHAAGEN • *Netherlands Institute for Neurosciences, Royal Netherlands Academy of Arts and Sciences (KNAW), Amsterdam, The Netherlands*

- MEIKE VISEL • *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA*
- ROGIER M. VOS • *Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands; InteRNA Technologies BV, Utrecht, The Netherlands*
- CHRISTINE WALLRAPP • *BTG International Germany GmbH, Alzenau, Germany*
- JIANG-HUI WANG • *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia; Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, VIC, Australia*
- JAN WIJNHOLDS • *Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences (KNAW), Amsterdam, The Netherlands*
- CHENMIAN WU • *Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China*
- WEN-HSUAN WU • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA*
- YU XU • *Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, Columbia University, New York, NY, USA; Department of Ophthalmology, Xinhua Hospital affiliated to Shanghai Jiao Tong, University School of Medicine, Shanghai, China*